Our team closely monitors individuals undergoing semaglutide therapy to ensure their well-being and minimize any potential risks
Twelve percent of American adults are now using GLP-1, with U.S
Our ultimate aim is to ensure that you secure the compensation you are entitled to for your injuries, medical expenses, and other damages
According to the MHRA product information, the most frequently reported adverse reactions include: Nausea and vomiting : Very common (affecting more than 1 in 10 people), typically most pronounced during the first 48 weeks of treatment or following dose escalation Diarrhoea : Common (affecting up to 1 in 10 people), with frequency increasing at higher doses Abdominal pain or discomfort : Often described as cramping or bloating sensations Decreased appetite : A direct result of the medication's action on satiety centres Constipation : Less common than diarrhoea but can occur in some individuals Dyspepsia (indigestion) : Characterised by upper abdominal discomfort or burning The timing of these side effects follows a predictable pattern in most patients
Each visit is billed individually the patient can return for a follow-up visit, schedule a different type of visit, or not return at all, without any auto-renew consequences
Obesity and insulin resistance in pediatric acute lymphoblastic leukemia worsens during maintenance therapy
